Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies Gain access to PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to verify the utility of its proprietary Cobalamin platform technology for targeted delivery of siRNA therapies. The program because is known as important, despite the broadly publicized potential of RNA therapy, researchers up to now have been stymied within their efforts to create a pharmaceutical item that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill What not to take with Valtrex? . Access has multiple applications ongoing around use of its Cobalamin technology to facilitate oral absorption of pharmaceuticals, including previously announced collaborations with potential pharma and biotech partners.
Electric motor vehicle-related deaths were subcategorized by occupant, pedestrian, pedal cyclist, various other, or unspecified. For all age groups, the overall accidental death rate declined except in those significantly less than a year old, where the price increased from 23.1 to 27.7 deaths per 100,000 from 2000 to 2009. In patients under age group 1, suffocation was the principal driver of the elevated overall death rate – increasing by 54 percent from 13.8 to 21.3 per 100,000 over the 9-year period. The decrease was generally because of the drop in accidental engine vehicle-related deaths, which decreased overall by 41 percent, from 9.3 per 100,000 people in 2000 to 5.5 per 100,000 people in 2009 2009.